Here are the top health stories for the day:
NMC gives deadline to FMGE June 2023 candidates applying for eligibility certificate
Referring to the mandatory submission of an eligibility certificate to appear in the Natboard- conducted screening test, the National Medical Commission (NMC) has invited applications from the FMGE June 2023 candidates.
The notification to this effect issued under the authority of Dr Vijaya Lakshmi Nag, Member of the Ethics and Medical Registration Board (EMRB) of the NMC, calls for applications from FMGE aspirants seeking eligibility certificates for the forthcoming session and has specified the deadline for the same.
For more details, check out the link given below:
NMC Gives Deadline To FMGE June 2023 Candidates Applying For Eligibility Certificate
Woman loses vision due to smartphone use
Long-term usage of smartphones has led to vision impairment in a woman aged 30 years. The case study of her was shared by a Hyderabad-based doctor on twitter, explaining how the ‘smartphone vision syndrome’ (SVS) is caused and how she corrected her vision.
Service rendered by Super Speciality doctors during COVID-19 pandemic can be considered as bond duty: Madras HC
Providing relief to five doctors who had attended COVID-19 patients during their Super-Specialty Course study, the Madras High Court bench has held that the COVID-19 service should be counted as their Compulsory Bond Period which they had been required to undergo compulsory government service after completing their course.
Holding that the refusal by the Government authorities cannot withstand judicial scrutiny, the HC bench opined that “it would also be discretionary as against the petitioners herein when they are compared with other medical professionals, who had actually completed their Post Graduate study as the petitioners.”
For more details, check out the link given below:
SII’s cervical cancer vaccine to be available in market this month at Rs 2000 for two doses
The Serum Institute’s made-in-India vaccine against cervical cancer, CERVAVAC, will be available in the market this month at an MRP of Rs 2,000 per vial of two doses, official sources said. The first indigenous human papillomavirus (HPV) vaccine was launched by Union Home Minister Amit Shah on January 24 in the presence of Serum Institute of India (SII) CEO Adar Poonawalla and its Director of Government and Regulatory Affairs Prakash Kumar Singh.
According to an official source, Singh has written a letter to the Union Health Ministry mentioning that the price of its HPV vaccine for the private market will be Rs 2,000 per vial of two doses which is much lower than other available HPV vaccines.
For more details, check out the link given below:
